세계의 mRNA 합성 및 제조 시장 예측(-2029년) : 제품별, 용도별, 최종사용자별, 서비스별, 지역별

The mRNA synthesis and manufacturing market is expected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024, at a CAGR of 3.4% during the forecast period. mRNA therapeutics hold promise as the next generation of drugs for tissue restoration in regenerative medicine. The development of non-immunogenic mRNA can be achieved through the use of modified nucleosides, which enhances safety and efficacy. By altering the mRNA structure, researchers can create stable, non-immunogenic mRNA through in vitro transcription. Furthermore, effective delivery strategies tailored specifically for mRNA are crucial for the advancement of these therapies. The processes involved in loading and releasing mRNA from biomaterials are essential for their application in tissue restoration and require further refinement to maximize their potential.

"The transcription consumables segment accounted for the largest share by product segment in the mRNA synthesis and manufacturing market in 2023."

Based on product, the mRNA synthesis and manufacturing market is segmented into consumables, and instrument. In 2023, the consumables segment accounted for the largest share of mRNA synthesis and manufacturing market; this segment is further segmented into transcription consumables, purification consumables, and analysis & characterization consumables. Dominance of the consumables segment throughout the forecast period is attributed to the fact that they are essential for mRNA synthesis and manufacturing. Unlike instruments, which are a one-time investment, consumables must be replenished regularly, leading to continuous demand. Also, the entire market operates majorly on instruments offered by Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), whereas more companies operate in the consumables space for mRNA synthesis and manufacturing.

"The mRNA synthesis & modification service segment is expected to grow at the highest growth rate in the mRNA synthesis and manufacturing market throughout the forecast period."

Based on service, the mRNA synthesis and manufacturing market is segmented into mRNA synthesis & modification, mRNA purification, mRNA analysis & characterization, and manufacturing & scale-up. In 2023, the mRNA synthesis & modification segment accounted for the largest share of the mRNA synthesis and manufacturing market. A significant driver for the mRNA synthesis and modification services within the mRNA synthesis and manufacturing market is the growing need for customized mRNA sequences and modifications to enhance the efficacy and stability of therapeutic and vaccine candidates, which requires specialized synthesis and modification services. As the application of mRNA technology expands, researchers and developers increasingly seek tailored mRNA sequences that can be optimized for specific therapeutic outcomes, such as improved protein expression or enhanced immune response.

"The Asia Pacific region is growing at the highest CAGR in the mRNA synthesis and manufacturing market from 2024 to 2029."

The mRNA synthesis and manufacturing market is segmented into six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is the fastest-growing regional segment in the global mRNA synthesis and manufacturing market, Factors such as rising healthcare expenditure; growing R&D expansion in key markets such as India, China, and Japan; low labor costs; and the favorable regulatory environment in the region are expected to contribute to market growth. China's mRNA synthesis and manufacturing market is driven by the country's substantial government investments in biotech innovation, rapid expansion of domestic biotech infrastructure, and increasing international collaborations. In recent developments, China has demonstrated a strong commitment to advancing mRNA technology.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: Directors - 50%, Managers - 30%, and Others - 20%
• By Region: North America -40%, Europe -35%, Asia-Pacific -20%, ROW -5%

List of Companies Profiled in the Report:

• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (US)
• GenScript (US)
• New England Biolabs (US)
• AldevronLLC. (Danaher Corporation) (US)
• Promega Corporation (US)
• Sartorius AG (Germany)
• WuXi Biologics (China)
• Takara Bio Inc. (Japan)
• GENEWIZ (Azenta USInc.) (US)
• TriLink BioTechnologies (US)
• Lonza (Switzerland)
• Telesis Bio Inc. (US)
• Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India)
• ST Pharm (South Korea)AGC Biologics (US)

Research Coverage:

This research report categorizes the mRNA synthesis and manufacturing market by Product (transcription consumables, purification consumables, analysis & characterization consumables, and instrument), Application (cell and gene therapy, vaccine, and other applications), End User (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the mRNA synthesis and manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the mRNA synthesis and manufacturing market. Competitive analysis of top players and upcoming startups in the mRNA synthesis and manufacturing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mRNA synthesis and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mrna technology, advancements in mrna synthesis technology, increased outsourcing for mrna synthesis and modification, and collaborations among industry players), restraints (High production cost, stringent regulations), opportunities (Advancements in drug delivery technologies, increased government funding and private investment, applications in regenerative medicines), and challenges (Stability, storage, and manufacturing scalability) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the mRNA synthesis and manufacturing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the mRNA synthesis and manufacturing market
• Competitive Assessment: Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), GenScript (US), New England Biolabs (US), Aldevron, LLC. (Danaher Corporation) (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (Azenta US, Inc.) (US), TriLink BioTechnologies (US), Lonza (Switzerland), Telesis Bio Inc. (US), Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India), ST Pharm (South Korea), AGC Biologics (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET SIZE ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY SOURCES
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MRNA SYNTHESIS & MANUFACTURING MARKET OVERVIEW
• 4.2 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT AND COUNTRY, 2023
• 4.3 MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET: GLOBAL GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rise in clinical trials for mRNA vaccines
    • 5.2.1.2 Continuous improvements in design, delivery systems, and manufacturing processes
    • 5.2.1.3 Increased outsourcing of mRNA synthesis and production
    • 5.2.1.4 Advantages of mRNA-based technology over recombinant expression
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High production cost
    • 5.2.2.2 Stringent regulations
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Ongoing innovations in nanoparticles and cell-specific delivery technologies
    • 5.2.3.2 Expanding applications of mRNA technology
    • 5.2.3.3 Increased government funding and private investments
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stability, storage, and manufacturing scalability issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 REGULATORY FRAMEWORK
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 In vitro transcription
    • 5.6.1.2 Poly(A) tail synthesis
    • 5.6.1.3 RNA stabilization technologies
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Next-generation sequencing
    • 5.6.2.2 Gene cloning and vector construction
    • 5.6.2.3 DNA amplification
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Spectrophotometry
    • 5.6.3.2 Electrophoresis
    • 5.6.3.3 High-performance liquid chromatography
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT
  • 5.7.2 AVERAGE SELLING PRICE TREND FOR CONSUMABLES
  • 5.7.3 AVERAGE SELLING PRICE, BY REGION
• 5.8 PATENT ANALYSIS
• 5.9 SUPPLY CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.2 BARGAINING POWER OF SUPPLIERS
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT)
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET

6 MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 TRANSCRIPTION CONSUMABLES
    • 6.2.1.1 mRNA synthesis kits
      • 6.2.1.1.1 Increasing demand for rapid and efficient mRNA vaccine development to augment growth
    • 6.2.1.2 mRNA profiling kits
      • 6.2.1.2.1 Growing need for precision medicine and personalized therapies to propel market
    • 6.2.1.3 RNA polymerases
      • 6.2.1.3.1 Growing demand for high-quality and scalable mRNA production to boost market
    • 6.2.1.4 Plasmid DNA/DNA templates
      • 6.2.1.4.1 Rapid growth of mRNA-based therapeutics and vaccines to expedite growth
    • 6.2.1.5 Nucleotides
      • 6.2.1.5.1 Need to support diverse research & development initiatives to promote growth
    • 6.2.1.6 Vectors
      • 6.2.1.6.1 Need for reliable and high-capacity vectors to propel market
    • 6.2.1.7 Other transcription consumables
  • 6.2.2 PURIFICATION CONSUMABLES
    • 6.2.2.1 Purification kits & reagents
      • 6.2.2.1.1 Rising focus on quality assurance to encourage growth
    • 6.2.2.2 Chromatography filters & membranes
      • 6.2.2.2.1 Growing emphasis on process optimization and cost-efficiency in large-scale production to drive market
    • 6.2.2.3 Other purification consumables
  • 6.2.3 ANALYSIS & CHARACTERIZATION CONSUMABLES
    • 6.2.3.1 Analysis kits & reagents
      • 6.2.3.1.1 Emerging applications of mRNA beyond vaccines to support growth
    • 6.2.3.2 Other analysis & characterization consumables
• 6.3 INSTRUMENTS
  • 6.3.1 NEED TO REDUCE PRODUCTION COST AND HIGHER SCALABILITY TO PROMOTE GROWTH

7 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 CELL & GENE THERAPIES
  • 7.2.1 RISING ADOPTION OF MRNA TECHNOLOGY TO TREAT GENETIC DISORDERS AND CANCER TO FUEL MARKET
• 7.3 VACCINES
  • 7.3.1 INCREASING DEVELOPMENT AND DEPLOYMENT OF MRNA VACCINES TO ACCELERATE GROWTH
• 7.4 OTHER APPLICATIONS

8 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.2.1 NEED TO RESPOND TO EMERGING INFECTIOUS DISEASES TO DRIVE MARKET
• 8.3 ACADEMIC & RESEARCH INSTITUTIONS
  • 8.3.1 INCREASING INVESTMENTS IN RESEARCH TO EXPEDITE GROWTH
• 8.4 CROS & CDMOS
  • 8.4.1 RISING DEMAND FOR OUTSOURCED SERVICES TO AID GROWTH

9 MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE

• 9.1 INTRODUCTION
• 9.2 MRNA SYNTHESIS & MODIFICATION SERVICES
  • 9.2.1 GROWING NEED FOR CUSTOMIZED MRNA SEQUENCES AND MODIFICATIONS TO FUEL MARKET
• 9.3 MRNA PURIFICATION SERVICES
  • 9.3.1 NEED FOR PERSONALIZED MRNA VACCINES TO BOOST MARKET
• 9.4 MRNA ANALYSIS & CHARACTERIZATION SERVICES
  • 9.4.1 INCREASING REGULATORY SCRUTINY TO EXPEDITE GROWTH
• 9.5 MANUFACTURING & SCALE-UP SERVICES
  • 9.5.1 GROWING TRANSITION FROM SMALL-SCALE RESEARCH & DEVELOPMENT TO LARGE-SCALE COMMERCIAL PRODUCTION TO DRIVE MARKET

10 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 RAPID DEVELOPMENT AND COMMERCIALIZATION OF MRNA-BASED PRODUCTS TO ENCOURAGE GROWTH
• 10.3 ACADEMIC & RESEARCH INSTITUTIONS
  • 10.3.1 INCREASING EMPHASIS ON TRANSLATING MRNA-BASED DISCOVERIES INTO PRACTICAL APPLICATIONS TO AID GROWTH
• 10.4 SMALL-SCALE CROS & CDMOS
  • 10.4.1 NEED FOR SPECIALIZED AND FLEXIBLE PRODUCTION IN BIOTECH COMPANIES AND EARLY-STAGE MRNA PROJECTS TO BOOST MARKET

11 MRNA SYNTHESIS & MANUFACTURING MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing demand for mRNA-based vaccines and therapeutics to accelerate growth
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing collaborations between academic institutions and market players to spur growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Growing establishment of manufacturing sites to boost market
  • 11.3.3 UK
    • 11.3.3.1 Presence of state-of-the-art facilities to support growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Favorable government support for biopharmaceutical production to drive market
  • 11.3.5 SWITZERLAND
    • 11.3.5.1 Robust biotech sector and production facilities to promote growth
  • 11.3.6 ITALY
    • 11.3.6.1 Increasing collaborations among biotech firms and manufacturing facilities to aid growth
  • 11.3.7 SPAIN
    • 11.3.7.1 Growing investments in biotechnology to fuel market
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Rapid expansion of domestic biotech sector to contribute to growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing strategic investments in biotechnology infrastructure to boost market
  • 11.4.4 INDIA
    • 11.4.4.1 Booming biotech sector and international collaborations to augment growth
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Increased government funding in research and vaccine development to bolster growth
  • 11.4.6 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increased funding for strengthening infrastructure to sustain growth
  • 11.5.3 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 GROWING INVESTMENTS FROM PRIVATE SECTOR AND ACADEMIC RESEARCH INITIATIVES TO DRIVE MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK IN MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING INITIATIVES TO ENHANCE LOCAL PRODUCTION CAPABILITIES TO PROPEL MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product/Service launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 DANAHER CORPORATION
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 MERCK KGAA
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 LONZA
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
      • 13.1.4.3.2 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 MARVAI LIFESCIENCES
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product/Service launches
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 GENSCRIPT
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
    • 13.1.6.4 MnM view
      • 13.1.6.4.1 Key strengths
      • 13.1.6.4.2 Strategic choices
      • 13.1.6.4.3 Weaknesses and competitive threats
  • 13.1.7 NEW ENGLAND BIOLABS
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product/Service launches
  • 13.1.8 PROMEGA CORPORATION
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Expansions
      • 13.1.8.3.2 Other developments
  • 13.1.9 WUXI BIOLOGICS
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Expansions
  • 13.1.10 TAKARA BIO INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product/Service launches
      • 13.1.10.3.2 Deals
  • 13.1.11 SARTORIUS AG
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 AZENTA US INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
  • 13.1.13 TELESIS BIO INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product/Service launches
      • 13.1.13.3.2 Deals
  • 13.1.14 ST PHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
  • 13.1.15 AGC INC. (THROUGH AGC BIOLOGICS)
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
      • 13.1.15.3.2 Expansions
  • 13.1.16 DR. REDDY'S LABORATORIES LTD.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products/Services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Expansions
• 13.2 OTHER PLAYERS
  • 13.2.1 ETHERNA
  • 13.2.2 BOC SCIENCES
  • 13.2.3 BIOMAY AG
  • 13.2.4 CURIA GLOBAL, INC.
  • 13.2.5 JENA BIOSCIENCE GMBH
  • 13.2.6 ENZYNOMICS CO., LTD.
  • 13.2.7 KANEKA EUROGENTEC S.A.
  • 13.2.8 VERNAL BIOSCIENCES
  • 13.2.9 CELLSCRIPT

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS